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CD177 modulates the function and homeostasis of
tumor-inﬁltrating regulatory T cells
Myung-Chul Kim1,2,26, Nicholas Borcherding3,4,5,26, Kawther K. Ahmed 3,24,26, Andrew P. Voigt 5,26,
Ajaykumar Vishwakarma4,6, Ryan Kolb1,2, Paige N. Kluz3, Gaurav Pandey3,25, Umasankar De1,2,
Theodore Drashansky 7, Eric Y. Helm7, Xin Zhang 2,8, Katherine N. Gibson-Corley9, Julia Klesney-Tait10,
Yuwen Zhu 11, Jinglu Lu 12, Jinsong Lu13, Xian Huang13, Hongrui Xiang13, Jinke Cheng 14,15,
Dongyang Wang16, Zheng Wang16, Jian Tang16, Jiajia Hu17, Zhengting Wang18, Hua Liu18, Mingjia Li19,
Haoyang Zhuang19, Dorina Avram2,7,20, Daohong Zhou 2,8, Rhonda Bacher 21, Song Guo Zheng22,
Xuefeng Wu 12,13,14,23 ✉, Yousef Zakharia 9 ✉ & Weizhou Zhang 1,2,3 ✉

Regulatory T (Treg) cells are one of the major immunosuppressive cell types in cancer and a
potential target for immunotherapy, but targeting tumor-inﬁltrating (TI) Treg cells has been
challenging. Here, using single-cell RNA sequencing of immune cells from renal clear cell
carcinoma (ccRCC) patients, we identify two distinct transcriptional fates for TI Treg cells,
Fate-1 and Fate-2. The Fate-1 signature is associated with a poorer prognosis in ccRCC and
several other solid cancers. CD177, a cell surface protein normally expressed on neutrophil, is
speciﬁcally expressed on Fate-1 TI Treg cells in several solid cancer types, but not on other TI
or peripheral Treg cells. Mechanistically, blocking CD177 reduces the suppressive activity of
Treg cells in vitro, while Treg-speciﬁc deletion of Cd177 leads to decreased tumor growth and
reduced TI Treg frequency in mice. Our results thus uncover a functional CD177+ TI Treg
population that may serve as a target for TI Treg-speciﬁc immunotherapy.

A list of author afﬁliations appears at the end of the paper.
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reg cells are a population of T cells with suppressive effects
on a variety of immune cells including CD8+ T cells,
CD4+ T cells, natural killer cells, and dendritic cells1. Treg
cells play an indispensable role in maintaining normal immune
homeostasis and peripheral tolerance. Their suppressive activity
in the tumor microenvironment is associated with the loss of
anti-tumor immunity1, which provides the rationale for the
development of Treg-targeted immunotherapy2. For example,
ipilimumab is the ﬁrst immune checkpoint blocker approved by
the Food and Drug Administration and has been thought to work
through inhibiting CTLA-4 on effector T cells as well as on Treg
cells by depleting Treg cells in the tumor microenvironment3,4.
Treg cells are identiﬁed by the expression of transcription factor
forkhead box P3 (FOXP3) that acts as a master regulator for Treg
development and suppressive function5,6. FOXP3 alone fails to
predict patient survival and its prognostic value is tumor typeand stage-dependent across different cancers7,8. Recent studies
also unveiled functional heterogeneity of FOXP3+ Treg cells in
peripheral blood (PB)9, as well as in different tumor types
including colorectal cancer10 and glioma11. Disruption of all Treg
function may negatively inﬂuence immune homeostasis, as seen
in the autoimmune complications associated with CTLA-4
blockade, which underscores the need for more reﬁned targets
for TI-Treg cells.
Recent RNA sequencing of blood-derived, normal-tissue-resident, and TI Treg cells in two independent studies revealed the
transcriptional overlap between normal-tissue and TI Treg
cells12,13. TI Treg cells showed differential upregulation of
appreciable number of genes, including chemokine receptor 8
(CCR8), CTLA4, lymphocyte activation gene 3 (LAG3), and T-cell
membrane protein 3 (TIM-3, encoded by HAVCR2), layilin
(LAYN), and MAGE family member H1 (MAGEH1)12,13. One
report from the Rudensky group identiﬁed CD177+ TI Treg cells
in breast cancer with no further functional elaboration12. A
comprehensive single cell RNA sequencing using mouse splenocytes also deﬁnes the expression of Cd177 in a small subset of
mouse splenic Treg cells14. CD177 (also known as NB1, HNA-2a,
or PRV1) is a glycosylphosphatidylinositol-linked cell surface
protein that is expressed heterogeneously by neutrophils and has
been identiﬁed as a useful biomarker for myeloproliferative
diseases15,16. We recently generated a Cd177 knockout (KO)
mouse model and demonstrated a potential role of CD177 in
neutrophil viability17. Limited literature indicates a correlation
between the loss of CD177 expression and poor prognosis in
colorectal and gastric cancer18,19. Our recent study demonstrated
that CD177 is expressed by epithelial cells of breast cancer where
its expression is associated with a better prognosis. We further
found that CD177 expressed by cancer cells has tumorsuppressive functions via regulating β-catenin activation20.
To investigate transcriptional heterogeneity of TI Treg cells, we
performed single-cell RNA-sequencing of PB and TI immune
cells in three ccRCC patients21. We chose ccRCC based on the
responsiveness of these tumors to immune checkpoint inhibitors
(ICI) in spite of their low mutational load, which implies the
importance of the tumor microenvironment in mediating the
sensitivity to ICI22. It has been shown that Treg gene signatures
are associated with a worse prognosis in ccRCC23,24 and Treg
inﬁltration into ccRCC tumors has been implicated in poor
response to IL-2-based immunotherapy and targeted therapy25,26.
Here we demonstrate, by pairing our dataset with the singlecell sequencing of immune cells from an HCC dataset27, the
presence of transcriptionally and functionally distinct TI Treg
populations. Most importantly, several genes, including BCL2L128
and CD177, are highly elevated in TI Treg cells relative to other
TI T cells or PB Treg cells. Our data thus support that CD177 is
speciﬁcally expressed within a speciﬁc population of TI Treg cells
2

of solid cancers, and that CD177 is able to mediate the suppressive activity of TI Treg cells in cancer.
Results
Analysis of TI Treg cells using single-cell RNA sequencing
from ccRCC patients. Using our newly developed ccRCC single
cell RNA sequencing dataset including 13,433 PB and 12,239 TI
cells, we identiﬁed a cluster of Treg cells based on the expression
of FOXP3 and CD25 (IL2RA) (Fig. 1a, b), containing 160 PB and
574 TI Treg cells. There were 273 differentially-expressed genes
(DEGs) (Log fold-change > 1, adjusted p-value < 0.05) by comparing TI versus PB Treg cells. We further ﬁltered the DEGs by
comparing the percent of TI and PB Treg cells that express each
gene (calculating the Δ percentage difference) (Fig. 1c) and a
complete analysis is available in Supplementary Data 1. The
upregulated DEGs in TI Treg cells with Δ percentage difference >
20% were labeled (Fig. 1c). Of those genes, two genes were only
expressed in TI Treg cells and had 0% expression in PB Treg cells,
i.e. NR4A1 (Δ percentage difference = 51.4%) and CD177 (Δ
percentage difference = 20.2%) (Fig. 1c). A summary of the top
eight upregulated or downregulated DEGs within TI Treg cells
was shown (Fig. 1d, e).
We also analyzed a recently-published single-cell proﬁle of
T cells in HCC27, comprised of ﬂow-sorted T cells including Treg
cells from PB, normal liver parenchyma, a transitional/junctional
zone near the tumor, and TI Treg cells. After clustering of Treg
cells (Supplementary Fig. 1a, b), we performed a similar DEG
analysis comparing 634 TI versus 264 PB Treg cells (Supplementary Fig. 1c). We found a total of 467 DEGs in the HCC TI Treg
cells (a complete analysis is available in Supplementary Data 2),
among which there were 143 shared DEGs with the ccRCC TI
Treg cells (Fig. 1f). The overlapping coefﬁcient was 0.52,
reﬂecting the signiﬁcant effect of the tumor microenvironment
and patient heterogeneity on the gene expression proﬁle of TITreg cells as reported before26,29. In agreement with previous
reports, we also found the increased expression of CCR8, LAYN,
and MAGEH1 in TI Treg cells12,13 (Fig. 1g). Among the shared
143 DEGs, CD177 has the highest average log-fold change in
ccRCC (log-fold change = 4.86) and HCC (log-fold change =
4.55) from TI Treg cells (Fig. 1g). Several other Treg relevant
genes, including CTLA4, ICOS, NR4A1 (NUR77), TNFRSF18
(GITR), TNFRSF4 (OX40), and TNFRSF9 (4-1BB), were also
differentially upregulated in TI Treg cells (Fig. 1g). A similar set
of upregulated genes was seen in the RNA sequencing result from
pooled Treg cells in breast, colorectal, and lung cancers
(Supplementary Fig. 1d, e).
The transcriptional bifurcation of TI Treg cells. Unlike previous studies that relied on pooled TI Treg cells and PB Treg cells,
we were able to investigate the dynamic processes of Treg transcriptomes at the single cell level (Fig. 2). Using the reverse graph
embedding approach in the Monocle 2 algorithm30, we constructed a cell trajectory of the TI and PB Treg cells in ccRCC
(Fig. 2a) and HCC (Supplementary Fig. 2a) datasets. We studied
the gene expression in Treg cells along differentiation processes
(Fig. 2a, b). To understand the process represented by an estimated trajectory, we ﬁrst identiﬁed genes that were signiﬁcantly
dynamic along pseudotime by ﬁtting a negative binomial generalized additive model (GAM) of gene expression as a smooth
function of pseudotime and the signiﬁcance was assessed using
likelihood ratio testing30. Many dynamic genes that were
increased in their expression within TI Treg cells along pseudotime were previously identiﬁed in the differential expression
analysis such as CCR8, CD177, CCL20, and CTLA4 (Fig. 2b), with
the complete list available in Supplementary Data 3. A similar
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Fig. 1 TI Treg cells display a distinct expression program compared to PB controls in the ccRCC single cell RNA sequencing dataset. a tSNE projection
of immune cells from three ccRCC patients with normal PB cells (n = 13,433) and TI cells (n = 12,239). Treg population (blue) was isolated and separated
as TI (orange) versus PB Treg cells (gray). b tSNE projection with the highlighted expression of Treg markers, FOXP3 and IL2RA (CD25). c Differential gene
expression analysis using the log-fold change expression versus the difference in the percentage of cells expressing the gene comparing TI versus PB Treg
cells (Δ Percentage Difference). Genes labeled have log-fold change > 1, Δ Percentage Difference > 20% and adjusted P-value from Wilcoxon rank sum
test <0.05. d Top eight upregulated genes by log-fold change in TI Treg cells with adjusted P-value <0.05. e Top eight downregulated genes by log-fold
change in TI Treg cells with adjusted P-value <0.05. d, e Wilcoxon rank sum test with p-values adjusted using the Bonferroni method. f Comparison of
differential genes in TI Treg cells in ccRCC (orange) and HCC (green) compared to PB Treg cells. Signiﬁcant genes were deﬁned as log-fold change >1 or <
−1 with adjusted P-values <0.05. g Violin plots showing relative mRNA level of Treg markers in PB (gray) and TI Treg cells in ccRCC (top) and HCC
(bottom).

proﬁle of genes was expressed dynamically along pseudotime in
the HCC Treg cells, although with reduced separation between TI
and PB Treg cells in several genes including CTLA4 and CCR8
(Supplementary Fig. 2b). In contrast, other genes such as CCL20,
CCL4 and CD177 maintained the differential expression levels
between TI and PB Treg cells within the HCC dataset (Supplementary Fig. 2b). We observed a signiﬁcant increase in chemokines CCL20 and CCL4 over pseudotime trajectory (Fig. 2b,
Supplementary Fig. 2b). These chemokines are reported to play a
role in the trafﬁcking of Treg cells to the site of antigen
presentation31.
The trajectory from PB to TI Treg cells contained two distinct
branches (Fig. 2a) that were not detectable using Treg marker
genes, nor were they revealed in the previous clustering analysis
(Fig. 1a). To study the two branches of TI Treg cells, we
performed a branched expression analysis modeling by including
branch identity as a covariate in the full GAM model for the
likelihood ratio test (Fig. 2c). Commonly associated genes of
immune regulation and suppression were increased in their
expression in TI Treg cells of Cell Fate #1 (CF1) compared to the
Treg cells of Cell Fate #2 (CF2) (Fig. 2c). The CF2 Treg cells had
increased expression of ribosomal-associated genes (Fig. 2c).
Using the differential gene analysis, we were able to distinguish
three distinct trends in gene expression between the two TI Treg
fates: 1) non-speciﬁc increase across the two TI Treg fates, like
CCR8 and CTLA4; 2) increased in the CF1 only, like CD177 and
TNFRSF4 (OX40); and 3) increased in the CF2 only, like CXCR4
and EGR1 (Fig. 2d). To investigate the potential functional
difference between the two cell fates, we performed single-sample

gene set enrichment analysis (GSEA) using gene sets for T cell
phenotypes and for comparing single-cell gene expression at the
poles of the trajectory (Fig. 2e). Both TI Treg cell fates had a
reduction in the naïve T cell signature and an increase in T cell
exhaustion signature compared to PB Treg cells in ccRCC
(Fig. 2e, upper row) and HCC (Supplementary Fig. 2d). In
contrast, the cytotoxicity and cell cycle signatures were signiﬁcantly higher in CF1 Treg cells (Fig. 2e, lower row), along with
an increase of the percent of cells in the G2M phase (Fig. 2f). The
increase in G2M was not seen in the CF1 Treg cells in the HCC
dataset (Supplementary Fig. 2e), suggesting a possible role of
tumor microenvironment in the cell cycle regulation. We also
observed a clonal expansion in TI Treg cells across all ccRCC
patients (Supplementary Fig. 3a–c), in agreement with the
published observation12,27,32,33. The clonal expansion of T cell
receptor repertoire was enriched in the CF1 TI Treg cells
(Supplementary Fig. 3d). This supports the previous observation
of increased clonality within the CD177+ TI Treg cells12.
The suppressive TI Treg subset expresses a gene signature with
superior prognostic ability. As our data suggests transcriptional
and functional differences in a suppressive subset of TI Treg cells,
we investigated whether a gene signature developed from singlecell RNA sequencing data would provide improved prognostic
ability (Fig. 3a) by evaluating the Kidney Renal Clear Cell (KIRC)
dataset from the Cancer Genome Atlas (TCGA). The KIRC
dataset contains 533 primary tumor samples with overall survival
information. We performed feature selection of randomly
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Fig. 2 Bifurcation in the transcriptional state of TI Treg cells reveals a more suppressive cell fate. a Trajectory manifold of Treg cells from the ccRCC
using the Monocle 2 algorithm. Solid and dotted lines represent distinct cell trajectories/fates deﬁned by expression proﬁles. b Pseudotime projections of
transcriptional changes in immune genes based on the manifold. The signiﬁcance was determined based on differential testing relative to the site of origin
which was also used to generate pseudotime and adjusted for multiple comparisons. c Expression heatmap of signiﬁcant (q < 1e-6) genes based on branch
expression analysis comparing the two TI cell fates. The genes in the heatmap were also used in the ordering of the pseudotime variable. d Cell trajectory
projections of transcriptional changes in immune genes based on the manifold. Signiﬁcance based on differential testing between the ﬁrst and second cell
fates of TI Treg cells. x denotes the scaled mean mRNA levels at each pole of the manifold. e Gene set enrichment analysis of the poles of the trajectory
manifold. Boxplots were drawn for values between 25th and 75th percentile with median value lines. Outlier values were graphed as individual points for
values 1.5 times the interquartile range. P-values are based on one-way ANOVA with individual comparisons corrected for multiple hypothesis testing
using the Tukey HSD method. f Results of the cell cycle regression analysis of single cells for each cell fate using the Seurat R package.

selected 10% training KIRC cohort samples to identify gene signatures using three gene sets from the single-cell analysis: (1) 143
differential genes of TI Treg cells shared between ccRCC and
HCC, (2) 86 genes differentially expressed in the CF2, and (3) 222
genes differentially expressed in the CF1. These genes were passed
through a gene ﬁlter for genes speciﬁc to TI Treg cells compared
to other TI-immune cells derived from the ccRCC single-cell
cohort (Supplementary Data 4). After evaluating polynomial
support vector machines, k-nearest neighbors, boosted tree classiﬁcations, and bootstrap aggregating classiﬁcations supervised
machine-learning models, we selected a linear support vector
machine because the method had the least issue in overﬁtting the
survival data. The output of this process led to the selection of six
Treg-speciﬁc genes (Fig. 3a). Applying these signatures to the
remaining 90% of the KIRC samples, we found that the TI-Treg
signature (Fig. 3b, upper panel) and the CF1 signature (Fig. 3b,
lower panel) could discriminate between patients with better and
poorer overall prognosis, but not the CF2 signature. Moreover,
4

both the CF1 and total TI Treg signatures had superior discrimination ability when compared to previously reported tumor
Treg markers, such as FOXP3 and ratio-based signatures
CCR8:FOXP3 or CCR8:CD3G (Fig. 3c)12,13.
Although the TI-Treg signature had a larger hazard ratio
compared to the CF1 signature in KIRC (Fig. 3c), the
CF1 signature was superior in discriminating patient survival
within multiple cancer types (Fig. 3d, e). We applied the ccRCCsignatures across the 24 largest TCGA datasets, ﬁnding that the
TI Treg signature was only able to predict poor survival within
KIRC and liver hepatocellular carcinoma (LIHC) (Fig. 3d), the
cancer types from which the common TI Treg signature was
derived. The CF2 signature failed to discriminate groups based on
overall survival in any TCGA dataset. The CF1 TI Treg signature
was able to predict poor survival within KIRC and LIHC, as well
as 5 other cancers (Fig. 3e). Both CF1 and the common TI Treg
gene signatures discriminated overall survival for histological
grade 3 samples for KIRC, but not other grades, reducing the
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values derived from Cox proportional hazard regression modeling. d, e Overall survival prediction with Cox proportional hazard ratio and −log10(P value)
based on two-sided log-rank testing across the 24 largest TCGA datasets using d the TI Treg signature and e the CF1 signature. CESC, Cervical squamous
cell carcinoma and endocervical adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; KIRC, kidney renal clear cell carcinoma,
KIRP, kidney renal papillary cell carcinoma; LGG, low-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PAAD, pancreatic
adenocarcinoma; SKCM, skin-cutaneous melanoma; THYM, thymoma.

concern for selection bias towards more advanced histological
grades (Supplementary Fig. 3e).
Expression of CD177 is speciﬁc to TI-Treg cells in various
human solid cancers. We became particularly interested in
CD177 due to the increased expression in TI Treg cells and its
speciﬁcity within the CF1 Treg cells in ccRCC (Fig. 4a, b) and
HCC (Supplementary Fig. 4a–c). We developed an immunohistochemistry (IHC) protocol and validated that CD177 protein was
expressed in neutrophils with polymorphic nuclei from human
colon tissue (Supplementary Fig. 4d, lower panel). In addition, we
found that CD177 protein was expressed by epithelial cells from
the colon, breast, and prostate (Supplementary Fig. 4e, black
arrows), as well as immune cell inﬁltrates from various human
tissues including colon, breast, prostate, liver, lung, lymph node
and spleen (Supplementary Fig. 4e, brown arrows). We did
observe CD177+ Treg cells within the normal liver and transitional/junctional zones of HCC from the single cell data (Supplementary Fig. 4c), as well as CD177+ Treg cells from human
splenocytes of cancer patients (Supplementary Fig. 4f). A comprehensive analysis of all T cell subtypes within the ccRCC dataset
further supports the exclusive expression pattern of CD177 on TI
Treg cells within tumors, but not on other T cell subtypes
regardless of effector/memory phenotypes of CD4+ or CD8+
T cells (Fig. 4c). We performed ﬂow cytometry on TI lymphocytes
and demonstrated that only TI Treg cells expressed various levels
of CD177 (Fig. 4d, Supplementary Fig. 4g, h), but neither PB Treg
cells, non-Treg CD4 T (Tconv) cells, nor CD8 T cells expressed
signiﬁcant amount of CD177 (Fig. 4d, Supplementary Fig. 4g, h).
There was an average of 22.4% CD177+ Treg cells among TI Treg

cells in breast cancer and of 16.8% in ccRCC (Fig. 4e). There was a
negligible expression of CD177 on conventional CD4+ T cells
(Tconv) in breast and renal cancers (Fig. 4e). Using dual-color
IHC staining, we identiﬁed CD177- and FOXP3-double-positive
cells in breast cancer sections (Supplementary Fig. 4i, red arrow).
To identify factors that can induce CD177 expression on Treg
cells, we puriﬁed human PB Treg cells or CD4 Tconv cells (Fig. 4f)
from breast cancer patients, or splenic Treg cells or CD4 Tconv
from MC38 tumor-bearing mice (Fig. 4g), either non-stimulated
(ns) or treated with anti-CD3/CD28 and IL-2. We failed to induce
CD177 expression within human and mouse Treg cells, human
CD44+CD45RA− and CD44+CD45RA+ CD4 Tconv cells, or
mouse CD44+CD62L− and CD44−CD62L− CD4 Tconv cells
after 4 days of induction (Fig. 4f, g).
Using the germline Cd177-KO mice17, we found that Cd177deﬁciency led to a signiﬁcant decrease in tumor growth from the
Py8119 orthotopic breast cancer model (Fig. 5a, female mice) or
the MC38 colon cancer model (Fig. 5b, male mice). We further
developed a novel mouse model carrying a ﬂoxed allele of Cd177
(Cd177ﬂ/ﬂ) (Supplementary Fig. 5), which was crossed with the
Foxp3YFP/Cre mice to generate mice with Treg-speciﬁc deletion of
Cd177. We transplanted MC38 cells either into Cd177ﬂ/ﬂ or
Cd177ﬂ/+/Foxp3YFP/Cre males (collectively referred to as the
control group), or age-matched littermates of Cd177ﬂ/ﬂ/Foxp3YFP/
Cre males. Treg-speciﬁc Cd177 deletion resulted in reduced tumor
growth (Fig. 5c), similarly as in the germline Cd177 KO mice
(Fig. 5b). The CD177 KO was validated by real-time PCR for
germline KO strain (Supplementary Fig. 6a). Flow cytometry
showed signiﬁcant decrease in CD177 protein expression within
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Fig. 4 CD177 is a marker for a subpopulation of TI Treg cells. a Trajectory manifold of Treg cells from the ccRCC TI Treg cells with the number of CD177+
and CD177− Treg cells for each respective cell fate. The signiﬁcance is based on χ2 testing comparing the three poles of the manifold. b Proportional
distribution of CD177+ Treg cells by cell fate across the manifold. c CD177 mRNA expression on different effector/memory T cell subpopulations within
ccRCC dataset deﬁned by a gene signature including CD27, CD28, CCR7, CCR5, SELL and FAS. CM: central memory; Eff, effector; EM, effector memory.
d Schematic ﬂow cytometry data gating on lymphocytes (lym) were further analyzed for CD177 expression on Treg cells (CD4+CD25+FOXP3+),
conventional CD4 T cells (CD4 conv, CD4+CD25−) and CD8 T cells (CD8) isolated from TI lymphocytes in breast cancer or PBMC. e Percent CD177+
cells within TI CD4 Tconv or TI Treg cells in breast cancer (n = 13, mean ± SD) and renal cancer (n = 9, mean ± SD). Two-sided unpaired T-test was used.
f CD177 protein expression on different T cell subpopulations deﬁned by CD44 and CD45RA from PBMC of breast cancer patients. Treg cells
(CD4+CD25+CD127low) and CD4 conv cells (CD4 conv, CD4+CD25−) were puriﬁed from human PBMC of breast cancer patients, either non-stimulated
or stimulated (anti-CD3/CD28 + IL-2). Left: gating of Treg cells (top) or effector/memory population for CD4 Tconv (bottom); Right: CD177 expression on
the gated populations. g CD177 protein expression on different effector/memory T cell subpopulations deﬁned by CD44 and CD62L from mouse spleens.
Treg cells (CD4+CD25+GITR+) and CD4 conv cells (Tconv, CD4+CD25−) were puriﬁed from spleens of WT mouse, either non-stimulated or stimulated
(anti-CD3/CD28 + IL-2). f, g CD177 expression was determined by ﬂow cytometry.

CD25+FoxP3+ TI Treg cells from the Treg-speciﬁc CD177 KO
mice (Supplementary Fig. 6b).
To determine the inﬂuence of Treg-speciﬁc KO of Cd177, we
performed a thorough immune proﬁling from different tissues of
normal (non-tumor bearing) or tumor-bearing mice using ﬂow
cytometry (Supplementary Fig. 6c, gating strategy for lymphocytes). CD177 protein was detectable on Treg cells from various
tissues – including tumor, lung, spleen, and thymus of WT
tumor-bearing mice with the highest expression from TI Treg
cells (Supplementary Fig. 6d, upper panels). CD177 protein was
6

undetectable on CD4+ Tconv or CD8+ T cells except that TI
CD8 T cells have a low level of CD177 expression (Supplementary
Fig. 6d, upper panels), a phenotype that is different from human
TI CD8+ T cells (Fig. 4d, Supplementary Fig. 4h). CD177 protein
was largely diminished on Treg cells from these tissues of mice
carrying Treg-speciﬁc KO of Cd177 (Supplementary Fig. 6d,
lower panels). Neutrophils from these tumors or lungs, however,
exhibited similar levels of CD177 (Supplementary Fig. 6e). While
we did not observe signiﬁcant alterations within immune
populations from non-tumor-bearing mice (Supplementary
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for all group comparisons.
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Fig. 7a–f), Treg-speciﬁc Cd177-KO led to a signiﬁcant decrease of
TI Treg cells (Fig. 6a) and some other signiﬁcant changes of
various immune cells within various tissues of tumor-bearing
mice (Supplementary Fig. 8a–e). The ratios between TI effector
T cells (CD4 Tconv or CD8) and Treg cells were signiﬁcantly
increased in the tumors from Treg-KO mice (Fig. 6b). We
detected a decrease in thymic Treg cells caused by Cd177
deﬁciency (Fig. 6a) and a decrease in proliferation as indicated by
the reduced Ki-67+ TI Treg cells (Fig. 6c). The expression of
Treg-related genes involving Treg-suppressive function was
largely unchanged between CD177+ and CD177− TI Treg cells
in human breast cancer (Supplementary Fig. 8f) or ccRCC
(Supplementary Fig. 8g), with slight elevation of ICOS, TIGIT,
and CTLA4 (Supplementary Fig. 8f, g). Chemokine receptors on
TI Treg cells were not signiﬁcantly different between CD177+
and CD177− TI Treg cells from human breast cancer specimens
(Fig. 6d), or between WT and Treg-KO TI-Treg cells from MC38
tumors (Fig. 6e). We further grew MC38 or Py8119 tumors on
Ptprca – a congenic CD57BL/6 J strain carrying CD45.1 – for
adoptive transfer of splenic and thymic Treg cells at 1:1 ratio from
non-tumor bearing WT or germline KO mice carrying the
CD45.2 allele. 72 hrs after adoptive transfer, we performed ﬂow
cytometry (Supplementary Fig. 9a) and did not detect signiﬁcant
difference in donor TI-Treg numbers (Fig. 6f, h) or the viability
(Fig. 6g, i) between WT and KO TI Treg cells inﬁltrating into
either MC38 or Py8119 tumors. In vitro migration assay further
conﬁrmed similar migratory capability between WT and KO Treg
cells towards MC38 tumor lysates (Fig. 6j). These data suggest
that CD177 may not be a major regulator for the recruitment of
Treg cells to tumors and that the decreased Treg number due to
CD177-defeciency could be a result of decreased proliferation or
thymic production of Treg cells (Fig. 6a, c).
Expression of CD177 in TI Treg cells leads to an increased
suppressive activity. We found that CD177+ or CD177− TI Treg
cells, deﬁned as CD4+CD25+CD127low, from human cancer
specimens exhibited a similar level of FOXP3 protein in 1 breast
cancer, 2 colon cancers and 3 ccRCCs (Supplementary Fig. 9b).
CD177+ or CD177− TI Treg cells had similar expression of
FOXP3 mRNA in 5 breast cancers based on a published RNAseq
dataset (Supplementary Fig. 9c, GSE89225). After sorting,
CD177+ or CD177− TI Treg cells had the same expression level
of FOXP3 protein (Supplementary Fig. 9d). CD177+ Treg cells
had a greater suppressive activity on effector CD4+ T cells (Teff)
that were activated by anti-CD3/CD28 co-stimulation when
plated at a 2:1 ratio compared to CD177− Treg cells (Fig. 7a). We
further conﬁrmed the superior suppression from CD177+ TI
Treg cells from another 5 breast cancer specimens (Fig. 7b,
Supplementary Fig. 9e). Treatment with an anti-CD177-speciﬁc
monoclonal antibody (MEM166) blocked the suppressive activity
of CD177+ TI Treg cells (Fig. 7b, Supplementary Fig. 9e), but the
anti-CD177 antibody did not directly block the proliferation of
CD4+ or CD8+ T cells without Treg cells (Supplementary
Fig. 9f). The same anti-CD177 antibody is known to block
CD177-mediated neutrophil transmigration34. We further conﬁrmed the suppressive capacity of CD177+ TI Treg cells from
another independent experiment with CD177+ and CD177− TI
Treg cells from 7 renal cell carcinoma (RCC) specimens when
Teff cells were activated by monocyte derived dendritic cells (as
antigen presenting cells, APC) at 5:1 ratio (Teff/Treg) (Fig. 7c).
Interestingly, CD177− Treg cells partially suppressed Teff cells
when using APC (Fig. 7c), but not by anti-CD3 + anti-CD28 costimulation (Fig. 7a, b)—likely due to the known function of
CTLA-4 from Treg cells that can complete with CD28 for CD80/
CD86 ligation at the priming stage of T cell activation by APC.
8

Similar to the human CD177+ TI Treg cells, we found that Treg
cells from tumor-bearing WT mice exhibited a stronger suppressive capacity against both CD4+ and CD8+ T cells compared
to Treg cells from tumor-bearing Cd177-KO mice (Supplementary Fig. 9g). CD177+ TI Treg cells from mouse MC38 tumors
also exhibited superior suppressive capability towards APCactivated Teff cells (Fig. 7d). Naïve CD4+ or CD8+ T cells puriﬁed from spleens of WT or germline Cd177-KO mice exhibited
similar proliferative capacity upon APC stimulation (Supplementary Fig. 9h). We also puriﬁed Treg cells from tumor-bearing
control or Treg-speciﬁc Cd177-KO mice (cKO) and conﬁrmed
the similar expression level of FoxP3 (Fig. 7e, upper left panel). TI
Treg cells from control mice showed a stronger suppressive
capacity against Teff cells than TI-Treg cells from cKO mice
(Fig. 7e, lower left and right panels). Splenic Treg cells, however,
exhibited similar suppressive capacity (Supplementary Fig. 9i).
Discussion
Due to the immunosuppressive role of Treg cells in peripheral
tolerance, the targeting of Treg cells for cancer immunotherapy is
a double-edged sword. Although the attenuation of the Tregmediated suppressive activity increases the anti-tumor immune
response, Treg cell dysfunction is often associated with autoimmune and inﬂammatory diseases. For example, CTLA-4 is
constitutively expressed on Treg cells and acts as a primary
mechanism of immune suppression by Treg cells via blocking the
co-stimulation of Teff cells35. The anti-CTLA-4 antibody, ipilimumab, inhibits Treg function by abolishing CTLA-4-mediated
suppressive signaling and depletes Treg cells in the tumor
microenvironment3,4, but the nonspeciﬁc abrogation of Treg
function by ipilimumab often leads to substantial immune-related
adverse effects such as colitis, which can occur in over 50% of
patients. Thus, reﬁning targetable biomarkers for TI Treg cells is
critical for the development of Treg cell-targeted immunotherapy.
With our expanded analysis of TI Treg cells derived from ccRCC
and HCC27, our current study represents one of the largest collections of expression proﬁles available for paired PB and TI Treg
cells from human cancer specimens. We found a common differential signature of 143 genes comparing TI versus PB Treg
cells. The overlapping genes included common Treg markers,
such as CTLA4, ICOS, TNFRSF4, TNFRSF9, TNFRSF18, as well as
previously identiﬁed TI-Treg markers, such as CCR8, LAYN, and
MAGEH1. CD177 was among the most consistently elevated
genes from the single-cell RNA sequencing or the pooled RNA
sequencing of TI Treg cells. CD177 is a surface protein that can
be targeted by an antibody-based approach for cancer
immunotherapy.
In the context of prognosis, FOXP3 alone has had mixed results
in the ability to predict overall survival for patients. More
recently, two analyses of RNAseq of TI Treg cells reported the use
of the ratios CCR8/FOXP3 for breast cancer and CCR8/CD3G for
lung and colorectal cancers, which had a modest predictive value
in terms of overall survival12,13. Similar to algorithms developed
to quantify the immune contribution of bulk RNA sequencing36,
we utilized support vector machines trained with linear kernels to
develop a signature among different populations of TI Treg cells.
The CF-1 signature predicted overall survival in 10 cancer types,
including immunogenic cancers such as KIRC/ccRCC, SKCM,
and LUAD, etc (Fig. 3). Most importantly, the CF-1 signature
outperforms the newly developed common TI-Treg signature in
most cancer types, as well as Treg signatures established in the
literature. CD177 gene is not included in either CF-1 or TI-Treg
signatures since its expression is not Treg speciﬁc and did not
pass the Treg-speciﬁc ﬁlter (Fig. 3a, Supplementary Data 4). We
understand that the signature development in predicting
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Fig. 7 CD177+ TI Treg cells are highly suppressive to effector T cells. a Suppressive capacity of CD177+ or CD177− TI Treg cells isolated from breast
cancer specimens. CD4 Tconv cells were stimulated by anti-CD3/CD28 co-stimulation. CD4+CD25+CD127low total, CD177+ or CD177− TI Treg cells
were puriﬁed from 3 individual breast cancer specimens and combined for the suppression assay. Left: Histograms showing CFSE dilution peaks indicating
Teff cell proliferation and Right: Percentages of proliferative CD4 Teff cells co-cultured with total, CD177+ or CD177− TI Treg cells at ratios of 2:1, 4:1, 8:1 or
no Treg (Combined data from a and b: n = 3 biological replicates for CD177+ TI Treg cells and n = 2 for CD177− TI Treg cells at 2:1 ratio; n = 1 biological
replicate for other data point). P value is for comparison between CD177+ or CD177− TI Treg cells at 2:1 ratio Teff/Treg, using two-sided T-test. b Impact
of CD177 blockade on the immune suppressive function of CD177+ TI Treg cells, using a monoclonal antibody (MEM166). Similar suppression experiments
were performed as in a. CD177+ or CD177− TI Treg cells were puriﬁed from fresh human breast cancer specimens (combined from 5 patients) using ﬂow
cytometry and co-cultured with effector CD4 T (CD4+CD25−) cells from PBMC for ex vivo suppression assay, with or without the addition of 2 μg/ml
isotype control (IgG) or anti-CD177 antibody (MEM166). Percent of proliferating cells were included and the total number of CD4 Tconv cells were
enumerated after 4 days of incubation (n = 2 biological replicates for CD177+ Treg group, n = 1 for other data points). c Suppressive capacity of CD177+ or
CD177− TI Treg cells isolated from renal cell cancer specimens (RCC). CD4 Tconv cells were stimulated by anti-CD3 and APC (monocyte derived dendritic
cells). A total of 7 RCC specimens were combined (n = 1 for NS, non-stimulated or no Treg; n = 4 for CD177+ TI Treg cells; n = 3 biological replicates for
CD177− TI Treg cells). The total number of CD4 Tconv cells were counted after 4 days of incubation. d Suppressive capacity of CD177+ or CD177− TI Treg
cells isolated from mouse MC38 tumors. Effector CD4 T cells were stimulated by anti-CD3 and APC (derived from T-cell depleted splenocytes of tumor
bearing mice) and combined with TI Treg cells at different ratios. Left: Histograms showing the CFSE dilution as an indicator of T cell proliferation and right:
Percent proliferation as deﬁned by the histogram (n = 3 biological replicates except n = 6 for no Treg group). Two-way ANOVA was used. e Impact of
Treg-speciﬁc Cd177-KO on the suppressive capacity of TI Treg cells from MC38 tumors similar as shown in Fig. 5c. Upper left: post-sorting Treg purify was
determined by intracellular staining of FoxP3; Lower left: histogram showing CFSE dilution peaks indicating CD4+ Teff cell proliferation; right: summary of
percent proliferating cells (n = 4 biological replicates from 14 tumors from cKO group and 20 tumors from WT group, with 4 tumors combined in one
biological replicate). All data are presented mean ± s.t.d. c, e one-way ANOVA was used.

prognosis is a rapidly evolving endeavor, but our initial validation
of this CF-1-signature across TCGA cancer datasets (Fig. 3)
indicates a commonality of this suppressive CF-1 signature in
predicting poor prognosis. TI Treg cells have long been suspected
of causing the unresponsiveness or resistance to ICIs34,37, which
was further validated in a recent study that deﬁnes the critical role
of Treg cells in resistance to anti-PD-1 immunotherapy38. Thus,
the CF-1 signature could be very informative in the context of ICI
therapy, either to predict the intrinsic resistance/unresponsiveness or to predict acquired resistance to anti-PD-1 therapy.
CD177 has been mostly studied in neutrophils where it has
been suggested to play a role in transendothelial migration, cell
viability, and bactericidal activities. Apart from a minor point in a
recent study on TI Treg cells in breast cancer where the authors
found that CD177 was expressed on a small subset of TI Treg
cells and a study showing that its expression is a positive prognosis marker in colorectal cancer19, very little is known about
CD177 function outside of neutrophils. We observed the presence

of CD177 in 15-25% of TI Treg cells, including breast, renal, lung,
and colorectal cancers. Analysis of transcriptional heterogeneity
of TI Treg cells revealed that CD177 expression was closely
associated with the more suppressive CF-1 Treg cells with elevated immune suppression markers. Pseudotime trajectory places
CD177 at the end stage of Treg development at the transcription
level, suggesting that CD177+ Treg cells are fully differentiated
and functional Treg cells, which is supported by the fact that
CD177+ Treg cells are more suppressive than CD177− Treg cells
in suppression assays as well as in vivo tumor models. Taken
together, our results suggest that CD177 is a speciﬁc marker for a
subset of suppressive TI Treg cells. Most importantly, we found
that CD177 is important in mediating the immune suppressive
function of TI Treg cells. We have tried many experiments to
understand why CD177+ TI Treg cells are more suppressive,
including (1) genetic analysis of CD177+ and CD177− TI Treg
cells from mice or humans (no signiﬁcant identiﬁable changes in
the genes whose protein products are involved in immune
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suppression), using either bulk RNAseq data or single cell RNA
sequencing data; (2) ﬂow cytometry for various cell surface proteins that are known to be involved in the suppressive mechanisms of Treg cells. Since both direct and indirect mechanisms of
suppression have been well-established in the literature, future
efforts are warranted to elucidate the molecular mechanisms with
speciﬁc focus on metabolic alterations of TI Treg cells, secretion
of immune-suppressive metabolites, or the identiﬁcation potential
CD177 receptors on effector T cells, etc.
One important question is the “targetability” of CD177 for
cancer immunotherapy. As a surface protein, our data supports
that blocking CD177 with antibodies can inhibit the function of
CD177+ TI Treg cells. Normal tissues have CD177 expression
including neutrophils, certain epithelial cells, as well as cells
within secondary lymphoid tissues. Depleting antibodies are
likely to carry the risk of neutrophil depletion and the development of neutropenia. Some TI myeloid cells, likely neutrophils or
granulocytic myeloid derived suppressor cells, also express
CD177. It is important to know the function of CD177 in these
cells. To the best of our knowledge, CD177 expression on neutrophils is constitutive and can be further increased by infections.
Germline KO of Cd177 has minimal phenotype in neutrophils
even under bacterial infections, which, on one hand, indicates the
safety of blocking CD177 signal; on the other hand, suggests
CD177+ TI neutrophil lineage is speciﬁc under the cancer context. Developing an anti-CD177 blocking antibody, but not a
depleting antibody, has the potential to inhibit the suppressive
activity of CD177+ TI Treg cells as a complementary method for
current cancer immunotherapy.
Our study highlights the importance of investigating the heterogeneity of immune cell populations, including Treg cells, in
the tumors to improve the understanding of the tumor microenvironment and identify new targets for Treg-based immunotherapy. This data also provides a unique resource of
transcriptome data at the single cell level from ccRCC PB and TI
immune cells.

using CCA on 1,000 highly variable genes identiﬁed using the built-in FindVariableGenes function. The top 20 dimensions of the aligned CCA were then used to
cluster cells with resolution/granularity set to 1.2. Cells and clusters are visualized
using t-Distributed Stochastic Neighbor Embedding (t-SNE). Differential gene
expression analysis was performed using the Wilcoxon rank sum test comparing TI
versus PB Treg cells. The p-values from the Wilcoxon rank sum test are adjusted
using Bonferroni correction. For the cell trajectory analysis and pseudo-time
estimates we utilized the Monocle 2 R package (v2.8.0) which is based on the
reverse graph embedding algorithm30. The DifferentialGeneTest function in
Monocle v2 was used to identify genes differing between PB and TI Treg cells.
Genes with a q-value (adjusted p-value) < .01 were used to construct the trajectory.
Branched expression analysis modeling (BEAM) was performed using the default
settings of the Monocle 2 R package. Single-sample gene set enrichment analysis
utilized the singleR R package (v0.2.0)39 for naïve, exhausted, cytotoxicity and cell
cycle gene sets that are relevant to T cells. The gene sets consisted of: (1) Cytotoxicity: NKG7, CCL4, PRF1, GZMA, GZMB, IFNG, CCL3; (2) Exhaustion: PDCD1,
TIGIT, LAG3, HAVCR2, CTLA4; (3) naïve CCR7, TCF7, LEF1, SELL; (4) Effector/
memory: CD27, CD28, CCR7, CCR5, SELL and FAS. Cell cycle regression for
individual Treg cells was performed with the Seurat p Package, as previously
described40. For ccRCC data, the quantiﬁed gene expression counts and V(D)J T
cell receptor sequences for single-cell RNA sequencing are available at the Gene
Expression Omnibus (GEO) at GSE121638. The same processing and quality
control procedures were applied to count-level data from the HCC single cell RNA
sequencing dataset: GSE98638 as well27.

Methods

Signature development. Log2 expression values from the Cancer Genome Atlas
(TCGA) were acquired from the UCSC Xena Browser. Updated survival information was obtained from the recent work of Liu, et al43. After merging expression
and clinical outcome data, an exhaustive best subset selection via the branch-andbound algorithm in the leaps library (v3.0) in R was performed to identify features
most predictive of overall survival. Feature selection was performed for three sets of
genes: 1) 143 differentially-expressed genes shared between ccRCC and HCC TI
Treg cells, 2) 86 genes differentially expressed in CF2 and 3) 222 genes differentially expressed in CF1 using the KIRC TCGA cohort. These genes were then
ﬁltered for TI-Treg-speciﬁc genes based on the comparisons with other tumorinﬁltrating immune cell lineages in the ccRCC data set. A total of 226 genes were
found to be signiﬁcantly upregulated with log-fold change ≥ 1 and FDR < 0.05 in at
least 3 of the 5 immune lineage comparisons.
To ensure the computational feasibility of best subset selection, a custom
scoring algorithm was devised. In each of the three gene sets, a random group of
<30 genes was used for best subset selection, and the ﬁve genes that compromised
the best ﬁve-predictor model were given a point. This process was repeated with a
new random group of <30 genes until all genes had been included in exactly 500
best subset selection models. The frequency of inclusion in the top-performing ﬁvepredictor model was assessed for each gene. The six genes that were most
frequently included in the top performing ﬁve-predictor model were utilized for
training subsequent machine learning algorithms. For each set of feature-selected
genes, support vector machines (SVMs) were trained to predict overall survival
using the e1071 (v1.7.0) R package. The 533 patients in the TCGA KIRC dataset
were randomly divided into training (10%, n = 53) and testing (90%, n = 480)
cohorts. SVMs were trained to discriminate overall survival status with linear
kernels, and the cost parameter was selected via cross-validation. Kaplan-Meyer
curves were constructed with the survival (v2.42.6) and survminer (v0.4.3) R
packages. The Cox proportional hazards regression model within the survival
package was used to compute the hazard ratios between good-outcome and pooroutcome prediction groups.

Patient recruitment. The current study was approved by the University of Iowa
Institutional Review Board (IRB) under the IRB number 201304826 and conducted
under the Declaration of Helsinki Principles. De-identiﬁed renal cancer patients
were informed and consented by Dr. Yousef Zakharia in the Department of
Internal Medicine at the University of Iowa. Some human tissues were also collected from patients undergoing surgical resection after informed consent and were
supplied as de-identiﬁed samples to Dr. Zhu laboratory with IRB approval (IRB
number: 13-0315) or Dr. Zhang with IRB approval (IRB number: IRB201901677).
Additional human specimens were collected after patient consents from the Renji
Hospital, Shanghai Jiao Tong University School of Medicine in an anonymous
manner to the Dr. Xuefeng Wu laboratory for cell preparation and T cell suppression assays, approved by the University Human Subject Protection Committee.
All human protocols were carefully read and evaluated by the full review panels
from the corresponding University Institutional Review Board (IRB), following
annual review for the progress, ethics and remaining tissue procurement.
10XGenomics library preparation, sequencing, and alignment. The detailed
single cell RNA sequencing procedures were recently published21. Brieﬂy, we
prepared single-cell libraries as per the 10X Genomics Chromium 5ʹ library and
Gel Bead Kit Version 2 (10X Genomics, Pleasanton, CA). Pooled libraries were
sequenced using the Illumina HiSeq 4000 in the University of Iowa Genomics
Division. Basecalls were converted to FASTQ ﬁles using the Illumina bcl2fastq
software and aligned to the human genome (GRCh38) using the CellRanger v2.2
pipeline. Cell quality was checked for the total expression of mitochondrial reads.
Cells with <200 or >5000 unique genes were ﬁltered out. After processing, clustering was performed using the Seurat R package (v2.3.4), correcting for patient
variability using canonical correlation analysis (CCA)49,50. The single-cell RNA
sequencing data were ﬁrst normalized to correct for sequencing depth by scaling
the total UMI counts per cell to 10,000. The normalized data were then log
transformed after adding a pseudo count of one. Finally, each gene’s log normalized counts were z-score transformed to have mean zero and a standard deviation
of one. The Seurat V2 package was used to align data from the three patients by

10

Bulk RNA sequencing Treg data. Raw expression data for GSE8922512 and
PRJEB1184413 were downloaded from the NCBI Sequence Read Archive and the
European Nucleotide Archive, respectively. SRA ﬁles were converted to FASTQ
ﬁles using the SRA toolkit. Samples were aligned with the kallisto pseudoalignment
protocol and GRCh38 build for the human genome to produce estimated counts41.
Treg expression values were processed using the Sleuth R Package (v0.30.0)42.
Statistical analysis. Statistical analyses were performed in R (v3.5.1). Two-sample
signiﬁcance testing utilized Welch’s T test, with signiﬁcance testing for more than
three samples utilizing one-way analysis of variance (ANOVA) with Tukey honest
signiﬁcance determination for correcting multiple comparisons. Differential gene
expression for single-cell RNA-seq data was performed in the Seurat R package
using the Wilcoxon rank sum test with p-values adjusted using the Bonferroni
method. Differential gene expression of bulk RNA-sequencing Treg expression
data utilized Wald testing in the Sleuth R Package42. Differential gene expression
between branches of the cell trajectory was performed in the Monocle R package
using likelihood ratio testing30. All other statistics were performed using embedded
functions of GraphPad Prism (v8.3.0).

Cell lines and cell culture. PY8119 cells were derived from a primary MMTVPyMT tumor in the C57BL/6 background as described previously44 and were
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provided by Dr. Lesley Ellies at the University of California, San Diego before she
provided to ATCC (CRL-3278). The cells were maintained in F12 media supplemented with 10% fetal calf serum (FCS), 10 ng ml−1 epithelial growth factor,
2 μg ml−1 hydrocortisone, and 5 μg ml−1 insulin. Cells were detached using 2.5%
trypsin and resuspended in 1:1 phosphate buffer saline: Matrigel (Corning,
Corning, NY) mixture and injected in mammary fatpad at 100 µl volume per
inoculation. MC38 colorectal cells were provided by Dr. Yuwen Zhu laboratory at
the University of Colorado Denver and were maintained in the same complete F12
media, detached using 2.5% trypsin, and resuspended in phosphate buffer saline
and injected into mammary fatpad at 100 µl volume per inoculation. The cell lines
were tested mycoplasma negative using Mouse Essential CLEAR Panel by Charles
River Research Animal Diagnostic Services (CR CADS, Wilmington, MA).

Flow cytometry. Mouse tumors and tissues were excised and digested using the
mouse Tumor Dissociation Kit (Miltenyi Biotec) to obtain single cell suspensions.
Red blood cells were lysed using ACK lysis buffer. Mouse cells were then washed
and incubated with combinations of the following antibodies: anti-mouse CD62LBV785 (clone MEL-14), anti-mouse MHCII I-A/I-E-BB515 (Clone 2G9, BD
Biosciences), anti-mouse CD11B-PEdazzle (clone M1/70), anti-mouse CD45AF532 (clone 30 F.11), anti-mouse CD3-APC (clone 17A2), anti-mouse CD8BV510 (clone 53-6.7), anti-mouse CD4-BV605 (clone GK1.5), anti-mouse CD11CPE-Cy7 (clone N418), anti-mouse Ly6G-FITC (clone IA8), anti-mouse Ly6CBV711 (clone HK1.4) anti-mouse F4/80-BV650 (clone BM8), anti-mouse CD80BV480 (clone 16-10A1, BD Biosciences), anti-mouse CD25-PE-Cy5 (clone PC61)
plus FVD-eFluor-780 (eBioscience), anti-CD19 (6D5), anti-B220-PerCP0EF710
(RA3-6B2, eBiosciences) and mouse FcR blocker (anti-mouse CD16/CD32, clone
2.4G2, BD Biosciences). After surface staining, cells were ﬁxed and permeabilized
using the FOXP3/Transcription Factor Staining Buffer Set (eBioscience). Cells were
stained with a combination of the following antibodies: anti-mouse FOXP3-EF450
(clone FJK-16S, eBioscience), anti-mouse Ki-67-PerCP-Cy5.5 (clone 16 A8). Most
antibodies are from Biolegend unless indicated otherwise, with 1:100 dilution per
recommendations unless speciﬁcally indicated in Supplementary Table 1, including
antigen name, clone number, company information, catalog numbers, ﬂuorophores, and dilutions.

Animals. All animals were maintained under speciﬁc pathogen-free conditions
according to the IACUC guidelines. Cd177-knockout mouse model was constructed in our previous publication17. The Treg KO of Cd177 is conﬁrmed by
using real-time PCR with primers listed (Supplementary Fig. 6A and Table 2). Mice
carrying Cd177ﬂ/ﬂ were developed by the Genome Editing Facility, University of
Iowa using CRISPR/Cas9 technology. The targeting strategy scheme is in the
Supplementary Fig. 5. Mice were genotyped using primers targeting both 5’ and 3’
LoxP sites. 5’ LoxP site primers are: 5′-GTGTTGCGTTTCCTGCTTG; 5′CTGGTTACCTTATGCCACTCC with a 172 bp wildtype product and 210 bp
mutant. 3’ LoxP site primers are: 5′-GGGTTGCCAAGACTTGATAATG; 5′AGGTGAGACACTAGAGAAGAGG with a wildtype 164 bp product and mutant
203 bp product following standard PCR protocol using DNA extracted from mouse
tail snips (Supplementary Table 2). The targeting allele was sequenced to conﬁrm
the correct insertion of LoxP site at both genomic locations. Treg-speciﬁc Cd177KO was achieved by mating Cd177ﬂ/ﬂ mice with Foxp3YFP/Cre (Stock No.: 016959,
Jackson Laboratories, Bar Harbor, Maine). Male mice carrying Cd177ﬂ/ﬂ and
hemizygous Foxp3YFP/Cre or female mice carrying Cd177ﬂ/ﬂ and homozygous
Foxp3YFP/Cre were used for experimental groups. We used 7-8 week old mice for
tumor study and euthanized the mice between 12-16 weeks of age. All animal
studies were approved by the University of Florida Institutional Animal Care and
Use Committee (IACUC) under protocol 201810399. All animals were housed in
the same room of a speciﬁc pathogen-free (SPF) within the Association for
Assessment and Accreditation of Laboratory Animal Care accredited facility at the
University of Florida and performed in accordance with IACUC guidelines.
Euthanasia was performed by the inhalation of medical grade CO2 per current
AVMA recommendations and UF IACUC policies. The WT and germline CD177KO mice were housed separately. The control group and Treg-speciﬁc Cd177-KO
group were co-housed. The room temperature is 21.1–23.3 °C with an acceptable
daily ﬂuctuation of 2 °C. Typically the room is 22.2 °C all the time. The humidity
set point is 50% but can vary ±15% daily depending on the weather. The photoperiod is 12:12 and the light intensity range is 15.6–25.8 FC.

Adoptive transfer of Treg cells. MC38 or PY8119 tumors were similarly grown in
Ptprca (CD45.1) mice (Jackson Laboratory) to 1 cm in diameter. EasySep Mouse
CD4+CD25+ Regulatory T Cell Isolation Kit (StemCell) was used to enrich splenic
and thymic CD4+CD25+ cells from WT and germline CD177-KO C57BL/6 J
(CD45.2+) mice. A total of 3 ×105 CD177 Treg cells from WT or KO mice (1:1
ratio of splenic and thymic Treg cells) were resuspended in 50 ul PBS for the
adoptive transfer into the tumor-bearing CD45.1+ Ptprca (CD45.1) mice via retroorbital route. 48 hrs later, mice were euthanized, and tumors were collected to
quantitate either recipient (CD45.1+) or donor (CD45.2+) TI Treg cells.
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Tissue collection and T cell suppression assay. Fresh human breast cancer and
renal cancer samples were collected from patients undergoing surgical resection
after informed consent, detailed above. Breast cancer samples were supplied deidentiﬁed by the Tissue Procurement Core at the University of Iowa Hospitals and
Clinics and were histologically characterized by the Department of Pathology at the
University of Iowa according to IHC of ER, PR and HER2 biomarkers. Deidentiﬁed blood samples from healthy donors were provided by the blood bank at
the University of Iowa Hospitals and Clinics. For renal cancer patients, deidentiﬁed matching blood samples were provided by the Genito-Urologic Molecular Epidemiology Resource at the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics. Human PB mononuclear cells (PBMCs) were
isolated from whole blood using Ficoll Plaque (GE Healthcare Biosciences, Pittsburgh, PA) density gradient centrifugation or SepMate Tubes (StemCell
Technologies).
Fresh tissues were directly distributed to the research laboratories after surgery,
followed by enzymatic digestion and physical dissociation using gentleMACS
(Miltenyi, Bergisch Gladbach, Germany) as per manufacturer’s instruction. Cell
suspensions were ﬁltered through a 100 μM cell strainer, magnetically enriched
using anti-CD45 positive selection (Miltenyi) for TI leukocytes, and immediately
frozen using FBS with 5% DMSO.
For in vitro suppression assay, naive CD4+ T cells were isolated from PBMC using
the human naïve CD4+ T cell isolation kit II (Miltenyi, 130-094-131). Naïve CD4+
T cells were stimulated by anti-CD3/28 dynabeads (Thermo Fisher) and 10 ng/ml IL-2
(R & D) overnight for co-culturing with Treg cells for Fig. 7a, b; or with monocytederived dendritic cells (Fig. 7c) from human PBMC with IL-4 (500U/ml, Immunotools,
Friesoythe, Germany) and GM-SCF (800 U/ML, Immunotools). TI-Treg cells were
labeled with anti-CD45, anti-CD4, anti-CD25, anti-CD127, anti-CD177 antibodies and
ﬂow-sorted. We combined Treg cells from 3 human breast cancer specimens to get
enough number of cells for Fig. 7a, 5 breast cancer specimens for Fig. 7b, 7 RCC
specimens for Fig. 7c, CD45+CD4+CD25+CD127low Treg cells were used as total TI
Treg cells, in addition to further separation of CD177+ or CD177− TI Treg cells. CFSElabeled pre-activated naïve CD4+ T cells were co-cultured with puriﬁed TI-Treg cells at
the indicated ratios (2:1, 4:1, or 8:1) on 96-well round-bottom plates – maintaining
continuous stimulation by anti-CD3/28 dynabeads (Thermo Fisher) or monocytederived dendritic cells in RPMI1640 supplemented with 10% fetal bovine serum (FBS),
10 mM HEPES, 2×10−5 M 2-mercaptoethanol for 96 hr. For antibody blocking assay,
we used either isotype control IgG or anti-CD177 (clone MEM166, Biolegend) at 2 μg/
mL concentration with the 2:1 Teff/Treg ratio for CD3/28 dynabead stimulation and 5:1
Teff/Treg ratio for monocyte-derived dendritic cell stimulation.
Antibody staining and multicolor immunophenotyping of TI-Treg cells. Multicolor phenotypic panels were established using different combinations of ﬂuorescently tagged anti-CD45 (H130), CD3 (HIT3a), CD4 (OKT4), CD25 (M-A251),
CD27 (O323), CD127 (A019D5), CCR8 (433H), PD-1 (EH12.2H7), CTLA-4
(BN13), FOXP3 (206D), and CD177 (MEM-166). Cells were stained using standard immunoﬂuorescent staining protocol and run on ﬂow cytometry either using
live cells or ﬁxed in 4% paraformaldehyde. Hoechst or eBiosciences Fixable Viability Dye eFluor 780 (ThermoFisher, eBiosciences) was used to exclude death cells.
Antibodies were purchased from Biolegend, Molecular Probes, BD Biosciences and
eBiosciences. Flow cytometric data were acquired on a 4-laser LSR II (BD Biosciences) or Cytek Aurora (Cytek, Fremont, CA) and data were analyzed using
FlowJo software (TreeStar, Ashland, OR). For experiments using frozen samples,
cells were thawed and suspended in RPMI supplemented with 10% FBS and
incubated for 1.5 h at 37oC, 5% CO2 before staining. Treg cells were identiﬁed as
CD3+CD4+FOXP3+ or CD3+CD4+CD25+CD127low. All human antibodies are
listed under Supplementary Table 1, including antigen name, clone number,
company information, catalog numbers, ﬂuorophores, and dilutions.
In vitro transmigration assay. Total splenocytes and thymocytes were isolated
from 6 to 8 weeks of male C57BL/6 J mice. Isolated cells were resuspended in 0.1%
FBS PBS, with 5 ×106 cells plated into the top chamber of the 24-well plate
transwell system (Corning, 3 μm size pore). A 10% MC38 tumor homogenate was
prepared in RPMI was added to the lower chamber as a chemoattractant. 24 hrs
later, cells from top chambers and migrated towards tumor homogenates were
collected for ﬂow cytometry to enumerate percent Treg migration, by using
migrated Treg cells divided by the total number of Treg cells (top and migrated
Treg cells).
Immunohistochemistry (IHC) staining. For IHC staining, formalin-ﬁxed,
parafﬁn-embedded tissue samples were sectioned at 5 μm by the University of Iowa
Comparative Pathology Laboratory. Sections were then de-parafﬁnized in a series
of xylene washes and rehydrated with ethanol and water. Antigen retrieval was
accomplished by immersing slides in a citrate buffer (pH 6) solution in a 110 °C
water bath for 15 min. Slides were allowed to cool-to-room temperature and were
then incubated with 3% hydrogen peroxide followed by 2–5 min washes in 1X
Dako buffer. Slides were then incubated with mouse monoclonal anti-CD177
antibody (clone C4C; Sigma) for 1 h and then Dako Mouse Envision System HRP
for 30 min. The slides were developed with 3,3’-diaminobenzidine (Dako DAB
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plus) for 5 min followed by 3-min incubation in 3,3′-diaminobenzidine tetrahydrochloride (Dako DAB enhancer). Samples were then counterstained with
hematoxylin, rinsed in water, cleared in xylene and then mounted with Permount.
Histological evaluations were performed by comparative pathologist Dr. Katherine
Gibson-Corley.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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Data availability
All original data are available upon request. We included new analysis from publicly
available datasets including: GSE89225, PRJEB11844, and GSE98638. The single cell
RNA sequencing result for renal cancer is deposited as GSE121638 and the TI-Treg cells
from the MC38 tumor model is deposited as GSE150420. TCGA datasets were
downloaded for the TCGA website or UCSC Xena Browser (https://xena.ucsc.edu/)
including KIRC/ccRCC, breast cancer, melanoma and 21 other cancer RNA sequencing
datasets and clinical parameters. Source data are provided with this paper.
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Code availability
All codes related to the single cell RNA sequencing is available here: https://github.com/
ncborcherding/.
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